GlassScriptPhysician profile
Marc S Eisenberg
NPI 1396751020
$4,540.59
in general payments reported to CMS, 2019-2025
24 companies · $769 in 2025
The $769 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $476 · 2020: $333 · 2021: $411 · 2022: $665 · 2023: $742 · 2024: $1,144 · 2025: $769.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,655.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,655.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $599.35 | 2022-2025 | Camzyos, Eliquis |
| Boston Scientific Corporation | $581.85 | 2023-2024 | Bodyguardian, Watchman Flx |
| Novartis Pharmaceuticals Corporation | $528.95 | 2019-2025 | |
| Pfizer INC. | $473.51 | 2019-2025 | |
| Amgen INC. | $455.11 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $436.80 | 2019-2024 | Xarelto |
| Bardy Diagnostics, INC. | $245.98 | 2020 | |
| Novo Nordisk INC | $239.21 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Saluda Medical Americas, INC. | $178.82 | 2023 | Evoke Scs |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.39 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $109.57 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $95.34 | 2024 | Arcalyst |
| Kiniksa Pharmaceuticals, LTD. | $87.94 | 2022-2023 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $61.55 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $53.61 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $49.65 | 2024-2025 | Nexletol |
| Heartflow, INC. | $43.28 | 2024-2025 | |
| Amarin Pharma, INC. | $34.44 | 2022 | |
| Scpharmaceuticals INC. | $34.28 | 2025 | |
| Csl Behring | $33.60 | 2023 | Kcentra |
| Recor Medical INC | $22.50 | 2025 | Paradise Ultrasound Renal Denervation System |
| Bayer Healthcare Pharmaceuticals INC. | $22.16 | 2025 | |
| Daiichi Sankyo INC. | $20.48 | 2022 | |
| Philips North America LLC | $20.22 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Eisenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.